skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: Elsevier ClinicalKey Journals remover assunto: Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Severe Pulmonary Toxicity After Myeloablative Conditioning Using Total Body Irradiation: An Assessment of Risk Factors
Severe Pulmonary Toxicity After Myeloablative Conditioning Using Total Body Irradiation: An Assessment of Risk Factors
Material Type:
Artigo 		Adicionar ao Meu Espaço

Severe Pulmonary Toxicity After Myeloablative Conditioning Using Total Body Irradiation: An Assessment of Risk Factors

Kelsey, Chris R., M.D ; Horwitz, Mitchell E., M.D ; Chino, Junzo P., M.D ; Craciunescu, Oana, Ph.D ; Steffey, Beverly, M.S ; Folz, Rodney J., M.D. Ph.D ; Chao, Nelson J., M.D ; Rizzieri, David A., M.D ; Marks, Lawrence B., M.D

International journal of radiation oncology, biology, physics, 2011-11, Vol.81 (3), p.812-818 [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por
2
Zevalin® (ibritumomab tiuxetan): After More Than a Decade of Treatment Experience, What Have We Learned?
Zevalin® (ibritumomab tiuxetan): After More Than a Decade of Treatment Experience, What Have We Learned?
Material Type:
Artigo 		Adicionar ao Meu Espaço

Zevalin® (ibritumomab tiuxetan): After More Than a Decade of Treatment Experience, What Have We Learned?

Rizzieri, David

Critical reviews in oncology/hematology, 2016-09, Vol.105, p.5-17 [Periódico revisado por pares]

Netherlands: Elsevier Ireland Ltd

Texto completo disponível

Citações Citado por
3
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Issa, Jean-Pierre J, Prof ; Roboz, Gail, Prof ; Rizzieri, David, Prof ; Jabbour, Elias, MD ; Stock, Wendy, Prof ; O'Connell, Casey, MD ; Yee, Karen, MD ; Tibes, Raoul, MD ; Griffiths, Elizabeth A, MD ; Walsh, Katherine, MD ; Daver, Naval, MD ; Chung, Woonbok, PhD ; Naim, Sue, BS ; Taverna, Pietro, PhD ; Oganesian, Aram, PhD ; Hao, Yong, MD ; Lowder, James N, MD ; Azab, Mohammad, MD ; Kantarjian, Hagop, Prof

The lancet oncology, 2015-09, Vol.16 (9), p.1099-1110 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial

Kantarjian, Hagop M ; Roboz, Gail J ; Kropf, Patricia L ; Yee, Karen W L ; O'Connell, Casey L ; Tibes, Raoul ; Walsh, Katherine J ; Podoltsev, Nikolai A ; Griffiths, Elizabeth A ; Jabbour, Elias ; Garcia-Manero, Guillermo ; Rizzieri, David ; Stock, Wendy ; Savona, Michael R ; Rosenblat, Todd L ; Berdeja, Jesus G ; Ravandi, Farhad ; Rock, Edwin P ; Hao, Yong ; Azab, Mohammad ; Issa, Jean-Pierre J

The lancet oncology, 2017-10, Vol.18 (10), p.1317-1326 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study
Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study

Cortes, Jorge, Prof ; Feldman, Eric, Prof ; Yee, Karen, MD ; Rizzieri, David, MD ; Advani, Anjali S, MD ; Charman, Anthony, PhD ; Spruyt, Richard, BSc ; Toal, Martin, FFPM ; Kantarjian, Hagop, Prof

The lancet oncology, 2013-04, Vol.14 (4), p.354-362 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Heyman, Benjamin ; Rizzieri, David ; Adams, David J. ; De Castro, Carlos ; Diehl, Louis ; Li, Zhiguo ; Moore, Joseph ; Beaven, Anne

Clinical lymphoma, myeloma and leukemia, 2018-10, Vol.18 (10), p.679-686 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
7
Renal Shielding and Dosimetry for Patients With Severe Systemic Sclerosis Receiving Immunoablation With Total Body Irradiation in the Scleroderma: Cyclophosphamide or Transplantation Trial
Renal Shielding and Dosimetry for Patients With Severe Systemic Sclerosis Receiving Immunoablation With Total Body Irradiation in the Scleroderma: Cyclophosphamide or Transplantation Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Renal Shielding and Dosimetry for Patients With Severe Systemic Sclerosis Receiving Immunoablation With Total Body Irradiation in the Scleroderma: Cyclophosphamide or Transplantation Trial

Craciunescu, Oana I., Ph.D ; Steffey, Beverly A., M.S ; Kelsey, Chris R., M.D ; Larrier, Nicole A., M.D ; Paarz-Largay, Cathy J., PA.-C., M.S ; Prosnitz, Robert G., M.D ; Chao, Nelson, M.D., M.B.A ; Chute, John, M.D ; Gasparetto, Cristina, M.D ; Horwitz, Mitchell, M.D ; Long, Gwynn, M.D ; Rizzieri, David, M.D ; Sullivan, Keith M., M.D

International journal of radiation oncology, biology, physics, 2011-03, Vol.79 (4), p.1248-1255 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
8
A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit–positive Acute Myeloid Leukemia
A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit–positive Acute Myeloid Leukemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit–positive Acute Myeloid Leukemia

Advani, Anjali S. ; Tse, William ; Li, Hong ; Jia, Xuefei ; Elson, Paul ; Cooper, Brenda ; Ali-Osman, Francis ; Park, Jino ; Rao, Arati V. ; Rizzieri, David A. ; Wang, Eunice S. ; Cotta, Claudiu V. ; Kalaycio, Matt ; Sobecks, Ronald M. ; Rouphail, Basel ; Maciejewski, Jaroslaw P. ; Fensterl, Jaime ; Carew, Jennifer S. ; Foster, Bethany ; Rush, Mary Lynn ; Tripp, Barbara ; Adams, Donna ; Corrigan, Donna ; Griffiths, Elizabeth A. ; Sekeres, Mikkael A.

Clinical lymphoma, myeloma and leukemia, 2021-02, Vol.21 (2), p.113-118 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
9
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study

Goldberg, Aaron D. ; Atallah, Ehab ; Rizzieri, David ; Walter, Roland B. ; Chung, Ki-Young ; Spira, Alexander ; Stock, Wendy ; Tallman, Martin S. ; Cruz, Hans G. ; Boni, Joseph ; Havenith, Karin E.G. ; Chao, Grace ; Feingold, Jay M. ; Wuerthner, Jens ; Solh, Melhem

Leukemia research, 2020-08, Vol.95, p.106385, Article 106385 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
10
A Phase II Trial of Gemcitabine and Mitoxantrone for Patients With Acute Myeloid Leukemia in First Relapse
A Phase II Trial of Gemcitabine and Mitoxantrone for Patients With Acute Myeloid Leukemia in First Relapse
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase II Trial of Gemcitabine and Mitoxantrone for Patients With Acute Myeloid Leukemia in First Relapse

Advani, Anjali S ; Shadman, Mazyar ; Ali-Osman, Francis ; Barker, Andrew ; Rybicki, Lisa ; Kalaycio, Matt ; Sekeres, Mikkael A ; de Castro, Carlos M ; Diehl, Louis F ; Moore, Joseph O ; Beaven, Anne ; Copelan, Ed ; Sobecks, Ronald ; Talea, Parisa ; Rizzieri, David A

Clinical lymphoma, myeloma and leukemia, 2010-12, Vol.10 (6), p.473-476 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (194)

Data de Publicação 

De até
Refinar
  1. Antes de2003  (5)
  2. 2003Até2007  (24)
  3. 2008Até2012  (50)
  4. 2013Até2018  (82)
  5. Após 2018  (35)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.